ClinicalTrials.gg
WithdrawnNCT05879614PWS-001Updated Dec 9, 2024

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

A Phase 2 interventional study of NNZ-2591 in Prader-Willi Syndrome, sponsored by Neuren Pharmaceuticals Limited. Withdrawn at 4 sites in United States. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Neuren Pharmaceuticals Limited · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Revised development strategy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
4 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Enrollment
56th of 58
0 · median 23
Started
2023
with 6 others
Phase 2
17 of 69
1 open now
Registered
54th of 69
by date

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 56th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2023, is one of 17 in phase 2, and was the 54th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 4 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Prader-Willi Syndrome.

Read the detailed description

The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with Prader-Willi Syndrome. The secondary purpose is to investigate measures of efficacy. Subjects will receive treatment with NNZ-2591 oral solution (50 mg/mL) doses for a total of 13 weeks.

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

Keywords

  • Prader-Willi Syndrome
04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of PWS with a documented disease-causing genetic abnormality of the chromosome 15q11-q13 confirmed by DNA methylation and microarray.
  2. Males or females aged 4-12 years, inclusive.
  3. Body weight of 12 kg to 100kg (inclusive) at Baseline.
  4. Subjects with a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at the Screening visit.
  5. Must currently be on treatment with growth hormone.
  6. Each subject must be able to swallow the study medication provided as a liquid solution.
  7. Caregiver(s) must have sufficient English language skills.
  8. Subject and caregiver must reside in the US and have been resident in the US for at least 3 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. Body weight \<12 kg or >100 kg at Baseline.
  2. values above 7% at the Screening visit.
  3. abnormalities in safety laboratory tests and vital signs at Screening.
  4. Positive pregnancy test at the Screening visit.
  5. Positive drugs of abuse screen not explained by concomitant medications.
  6. Abnormal interval or prolongation at Screening.
  7. Any other clinically significant finding on at the Screening visit.
  8. Positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening or Baseline.
  9. Previous COVID 19 infection with last 12 months that required hospitalization.
  10. Previous COVD-19 infection involving multi-organ systems, resulting in Multisystem Inflammatory Syndrome in Children (MIS-C) or with clinically significant long term effects.
  11. COVID-19 infection associated with acute kidney injury (AKI) or renal conditions.
  12. Renal conditions or abnormalities identified in laboratory testing, imaging or medical history.
  13. Liver conditions and Hepatic abnormalities.
  14. Vision abnormalities and Ocular conditions.
  15. Excluded concomitant treatments.
  16. Unstable seizure profile.
  17. Current clinically significant cardiovascular, gastrointestinal, or respiratory disease, or clinically significant organ impairment, or endocrine disease with the exception of obesity and controlled hypothyroidism.
  18. Current clinically significant hypo or hyperthyroidism, Type 1 or Type 2 diabetes mellitus requiring insulin (whether well controlled or uncontrolled), or uncontrolled Type 1 or Type 2 diabetes.
  19. Has planned surgery during the study.
  20. History of, or current, cerebrovascular disease or brain trauma.
  21. History of, or current catatonia or catatonia-like symptoms.
  22. History of, or current, .
  23. Current major or persistent depressive disorder (including bipolar depression).
  24. Significant uncorrected hearing impairment.
  25. Allergy to strawberry.
  26. Has participated in another interventional clinical study within 30 days prior to start of Screening.
  27. Subject is judged by the Investigator or Medical Monitor to be inappropriate for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    NNZ-2591

    NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.

    Drug: NNZ-2591

Interventions

  • NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.

    Also known as: Cyclo-L-Glycyl-L-2-Allylproline

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.

    Time frame: 13 weeks

  2. Pharmacokinetic - Measurement of Cmax

    Maximum observed concentration (Cmax) of NNZ-2591

    Time frame: 13 weeks

  3. Pharmacokinetic - Measurement of AUC

    Area under the concentration-time curve of NNZ-2591

    Time frame: 13 weeks

  4. Pharmacokinetic - Measurement of time to Cmax

    Time to Cmax of NNZ-2591

    Time frame: 13 weeks

  5. Pharmacokinetic - Measurement of t1/2

    Apparent terminal elimination half-life of NNZ-2591

    Time frame: 13 weeks

Secondary outcomes

  1. Exploratory efficacy measurement

    Assessed by PWS-specific Clinical Global Impression Scale \& Domain -Overall Improvement Score (CGI-I)

    Time frame: 13 weeks

  2. Exploratory efficacy measurement

    Assessed by Caregiver Global Impression-Change Score

    Time frame: 13 weeks

  3. Exploratory efficacy measurement

    Assessed by PWS-specific Clinical Global Impression Scale-Severity (CGI-S) Overall Score

    Time frame: 13 weeks

  4. Exploratory efficacy measurement

    Assessed by Caregiver Top 3 Concerns Likert Scale Scores

    Time frame: 13 weeks

  5. Exploratory efficacy measurement

    Assessed by PWS Profile Score

    Time frame: 13 weeks

  6. Exploratory efficacy measurement

    Assessed by PWS Anxiousness and Distress Behaviors Questionnaire Score (PADQ)

    Time frame: 13 weeks

  7. Exploratory efficacy measurement

    Assessed by Autism Diagnostic Observation Schedule (ADOS-2), Repetitive behaviors and Social scores

    Time frame: 13 weeks

  8. Exploratory efficacy measurement

    Assessed by Hyperphagia Questionnaire-Clinical Trials (HQ-CT) Score

    Time frame: 13 weeks

  9. Exploratory efficacy measurement

    Assessed by Food Safety Zone Questionnaire Score

    Time frame: 13 weeks

  10. Exploratory efficacy measurement

    Assessed by Vineland Adaptive Behavior Scales-3 Growth Scale Scores

    Time frame: 13 weeks

  11. Exploratory efficacy measurement

    Assessed by Zarit Burden Interview Score

    Time frame: 13 weeks

  12. Exploratory efficacy measurement

    Assessed by Child Sleep Habits Questionnaire (CSHQ)

    Time frame: 13 weeks

  13. Exploratory efficacy measurement

    Assessed by Impact of Childhood Neurological Disability Scale (ICND)

    Time frame: 13 weeks

  14. Exploratory efficacy measurement

    Assessed by Quality of Life Inventory-Disability (QI-Disability)

    Time frame: 13 weeks

  15. Exploratory efficacy measurement

    Assessed by Kaufman Brief Intelligence Test or Mullen Scales of Early Learning

    Time frame: 13 weeks

  16. Exploratory efficacy measurement

    Assessed by PWS Suicidality Assessment

    Time frame: 13 weeks

  17. Exploratory efficacy measurement

    Assessed by Caregiver Diary

    Time frame: 13 weeks

07

Study locations

4 sites
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • Rare Disease Research
    Atlanta, Georgia 30329, United States
  • Uncommon Cures
    Chevy Chase, Maryland 20815, United States
  • Suburban Research
    Media, Pennsylvania 19063, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Jun 2025, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2023
First posted
May 30, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05879614
Lead sponsor
Neuren Pharmaceuticals Limited
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Sep 1, 2023
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Dec 9, 2024

Study contacts

Jordan Press
study director · Neuren Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ercanetide

Start the discussion